Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

GL

Globe Life Inc

May 15 • 03:04PM ET

87.64

Dollar change -0.92
Percentage change -1.04	%

Financial • Insurance - Life • USA • NYSE

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO VB VO VBR IVV RSP VIG SPLV VTV

Index	S&P 500	P/E	8.37	EPS (ttm)	10.47	Insider Own	2.29%	Shs Outstand	93.79M	Perf Week	-2.07%
Market Cap	8.09B	Forward P/E	6.79	EPS next Y	12.91	Insider Trans	-2.98%	Shs Float	90.16M	Perf Month	46.14%
Income	1.00B	PEG	0.56	EPS next Q	2.90	Inst Own	84.59%	Short Float	4.66%	Perf Quarter	-30.08%
Sales	5.54B	P/S	1.46	EPS this Y	10.20%	Inst Trans	-0.09%	Short Ratio	1.37	Perf Half Y	-25.01%
Book/sh	53.56	P/B	1.64	EPS next Y	9.97%	ROA	3.61%	Short Interest	4.20M	Perf Year	-18.53%
Cash/sh	-	P/C	-	EPS next 5Y	14.89%	ROE	22.54%	52W Range	38.95 - 132.00	Perf YTD	-28.00%
Dividend Est.	0.90 (1.03%)	P/FCF	6.19	EPS past 5Y	10.60%	ROI	15.01%	52W High	-33.61%	Beta	0.82
Dividend TTM	0.91 (1.04%)	Quick Ratio	-	Sales past 5Y	4.84%	Gross Margin	-	52W Low	125.01%	ATR (14)	5.00
Dividend Ex-Date	Jul 05, 2024	Current Ratio	0.62	EPS Y/Y TTM	28.84%	Oper. Margin	24.60%	RSI (14)	52.89	Volatility	5.28% 6.76%
Employees	3636	Debt/Eq	0.47	Sales Y/Y TTM	6.02%	Profit Margin	18.07%	Recom	2.00	Target Price	106.70
Option/Short	Yes / Yes	LT Debt/Eq	0.32	EPS Q/Q	17.03%	Payout	8.93%	Rel Volume	0.35	Prev Close	88.56
Sales Surprise	-0.61%	EPS Surprise	-0.30%	Sales Q/Q	7.18%	Earnings	Apr 22 AMC	Avg Volume	3.06M	Price	87.64
SMA20	12.35%	SMA50	-8.97%	SMA200	-21.88%	Trades		Volume	924,763	Change	-1.04%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-24-24	Upgrade	Keefe Bruyette	Mkt Perform → Outperform	$130 → $110
Oct-31-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$122 → $137
Aug-18-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$131
Apr-25-23	Initiated	Wells Fargo	Equal Weight	$120
Oct-28-22	Downgrade	Evercore ISI	Outperform → In-line	$115 → $114
Sep-22-22	Initiated	Raymond James	Strong Buy	$138
Jun-15-22	Upgrade	Evercore ISI	In-line → Outperform	$105 → $112
Jan-26-22	Initiated	Jefferies	Hold	$106
Jan-21-22	Initiated	Wolfe Research	Underperform	$85
Jan-12-22	Upgrade	Piper Sandler	Neutral → Overweight	$105 → $117
Jul-24-20	Upgrade	Evercore ISI	Underperform → In-line
Jun-05-20	Initiated	Piper Sandler	Neutral	$87
Sep-20-19	Initiated	Credit Suisse	Outperform	$114

Show Previous Ratings

Today 05:45AM	Globe Life Inc. f/k/a Torchmark Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 1, 2024 to Discuss Your Rights - GL (PR Newswire)
May-14-24 02:33PM	Investors in Globe Life Inc. f/k/a Torchmark Corporation Should Contact Levi & Korsinsky Before July 1, 2024 to Discuss Your Rights GL (GlobeNewswire)
09:45AM	Globe Life (GL) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
May-08-24 05:04PM	S&P 500 Gains and Losses Today: Uber Stock Drops Following Unexpected Net Loss (Investopedia) +5.08%
May-07-24 12:13PM	Lowey Dannenberg, P.C. is Investigating Global Life Inc. ( Global Life ) (NYSE: GL) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm (GlobeNewswire) +5.34%
06:55AM	Loading…
May-06-24 06:55AM	GLOBE LIFE INC. DECLARES DIVIDEND (PR Newswire)
May-03-24 11:55AM	Lowey Dannenberg, P.C. is Investigating Global Life Inc. ( Global Life ) (NYSE: GL) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm (GlobeNewswire)
May-02-24 09:00AM	Here is What to Know Beyond Why Globe Life Inc. (GL) is a Trending Stock (Zacks)
May-01-24 09:30AM	Wall Street Analysts See Globe Life (GL) as a Buy: Should You Invest? (Zacks)
Apr-30-24 02:18PM	GE Aerospace Is the S&P 500s Top-Performing Stock in April. Globe Life Is the Worst. (Barrons.com)
Apr-29-24 10:10AM	Globe Life's Board Authorizes Up to $1.3 Billion in Stock Buybacks Under Existing Repurchase Plan (MT Newswires)
09:22AM	Jefferies Adjusts Price Target on Globe Life to $85 From $122 (MT Newswires)
07:00AM	Globe Life Inc. Share Repurchase Update (PR Newswire)
Apr-26-24 10:09AM	Globe Life Under Fire: DOJ Probe and Short-Seller Cast Shadow on Insurer - Hagens Berman (GlobeNewswire)
Apr-24-24 11:36AM	Globe Life Inc. (NYSE:GL) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:36AM	Loading…
09:36AM	Tesla, Airbnb upgraded: Wall Street's top analyst calls (The Fly)
08:25AM	--Piper Sandler Adjusts Price Target on Globe Life to $110 From $130 (MT Newswires)
Apr-23-24 04:41PM	S&P 500 Gains and Losses Today: Auto Parts Provider LKQ Sinks Amid Soft Demand (Investopedia) +14.11%
01:51PM	Top Midday Gainers (MT Newswires)
11:35AM	Update: Globe Life Shares Climb After Q1 Net Operating Income, Revenue Rise (MT Newswires)
07:20AM	Globe Life (GL) Q1 Earnings Miss Estimates, Revenues Rise Y/Y (Zacks)
Apr-22-24 08:53PM	GL Stock Earnings: Globe Life Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:49PM	GLOBE LIFE INC. ANNOUNCES VIRTUAL WEBCAST FOR 2024 ANNUAL MEETING OF SHAREHOLDERS (PR Newswire)
06:11PM	Globe Life Inc (GL) Q1 2024 Earnings: Surpasses Analyst EPS Projections (GuruFocus.com)
06:00PM	Here's What Key Metrics Tell Us About Globe Life (GL) Q1 Earnings (Zacks)
05:25PM	Globe Life (GL) Q1 Earnings and Revenues Lag Estimates (Zacks)
05:13PM	Globe Life Q1 Net Operating Income, Revenue Rise; 2024 Operating Income Outlook Updated (MT Newswires)
05:06PM	Globe Life profit surges on strong underwriting, investment returns (Reuters)
04:26PM	Globe Life: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	GLOBE LIFE INC. REPORTS FIRST QUARTER 2024 RESULTS (PR Newswire)
02:57PM	Loading…
02:57PM	Globe Life (GL) Tanks 50% After Fuzzy Panda Research Accuses Company of Wide-Ranging 'Insurance Fraud' Hagens Berman (GlobeNewswire)
10:26AM	Lowey Dannenberg, P.C. is Investigating Global Life Inc. ( Global Life ) (NYSE: GL) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm (GlobeNewswire)
09:35AM	Down -42.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Globe Life (GL) (Zacks)
Apr-19-24 10:14AM	Lowey Dannenberg, P.C. is Investigating Global Life Inc. ( Global Life ) (NYSE: GL) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm (GlobeNewswire)
09:40AM	Are Investors Undervaluing Globe Life (GL) Right Now? (Zacks)
08:48AM	Why Earnings Season Could Be Great for Globe Life (GL) (Zacks)
07:00AM	GLOBE LIFE INC. ANNOUNCES FIRST QUARTER 2024 EARNINGS RELEASE AND CONFERENCE CALL (PR Newswire)
Apr-18-24 03:01PM	96% Of S&P 500 Stocks Show Upside Potential Vs. Street Estimates: Which Offers The Best Opportunity? (Benzinga)
01:21PM	Globe Life (GL) Tanks 50% After Fuzzy Panda Research Accuses Company of Wide-Ranging 'Insurance Fraud' Hagens Berman (GlobeNewswire)
Apr-17-24 04:43PM	S&P 500 Gains and Losses Today: United Airlines Stock Soars After Earnings Beat (Investopedia) +5.44%
12:50PM	Globe Life (GL) Tanks 50% After Fuzzy Panda Research Accuses Company of "Wide-Ranging 'Insurance Fraud'" - Hagens Berman (Newsfile)
09:15AM	Exploring Analyst Estimates for Globe Life (GL) Q1 Earnings, Beyond Revenue and EPS (Zacks)
06:15AM	Billionaire Warren Buffett Recently Cut This Stock From Berkshire Hathaway's Portfolio. It Just Dropped 53% In 1 Day. Here's What Investors Need to Know. (Motley Fool)
Apr-16-24 05:50PM	S&P 500 Gains and Losses Today: Live Nation Stock Falls Amid Potential Antitrust Lawsuit (Investopedia) +7.45%
12:46PM	Globe Life (GL) Tanks 50% After Fuzzy Panda Research Accuses Company of "Wide-Ranging 'Insurance Fraud'" - Hagens Berman (Newsfile)
Apr-15-24 05:13PM	S&P 500 Gains and Losses Today: Salesforce Slips Amid Informatica Acquisition Talks (Investopedia) -5.55%
11:13AM	Globe Life (GL) Tanks 50% After Fuzzy Panda Research Accuses Company of Wide-Ranging 'Insurance Fraud' Hagens Berman (GlobeNewswire)
10:48AM	Lowey Dannenberg, P.C. is Investigating Global Life Inc. ( Global Life ) (NYSE: GL) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm (GlobeNewswire)
10:00AM	Globe Life (GL) Earnings Expected to Grow: Should You Buy? (Zacks)
08:47AM	Globe Life (GL) Soars 20.2%: Is Further Upside Left in the Stock? (Zacks)
Apr-12-24 05:02PM	S&P 500 Gains and Losses Today: Arista Networks Drops Amid Competitive Threat (Investopedia) +20.17%
04:07PM	Short Seller Behind Globe Lifes Plunge Has Winning Record (Bloomberg)
02:45PM	5 Investors Betting Big on Globe Life (GL) Stock (InvestorPlace)
01:57PM	Stocks to Watch Friday: JPMorgan, Intel, Globe Life (The Wall Street Journal)
12:10PM	Will Globe Life (GL) Beat Estimates Again in Its Next Earnings Report? (Zacks)
11:47AM	Globe Life shares plummet following short report (CNBC TV)
11:01AM	11 Oversold Value Stocks To Buy Now (Insider Monkey)
10:49AM	GL Stock Pops as Globe Life Hits Back at Short Seller (InvestorPlace)
10:20AM	Globe Life stock drops 50% because a short-seller alleged insurance fraud (Quartz)
10:16AM	Globe Life Stock Rallies After Thursday's Dive (The Wall Street Journal)
07:48AM	5 Things to Know Before the Stock Market Opens (Investopedia)
Apr-11-24 06:25PM	Labaton Keller Sucharow LLP is Investigating Claims against Globe Life Inc. and Encourages Investors to Contact the Firm (Business Wire) -53.14%
06:01PM	Globe Life (GL) Tanks 50% After Fuzzy Panda Research Accuses Company of Wide-Ranging 'Insurance Fraud' Hagens Berman (GlobeNewswire)
05:39PM	Globe Life Sank by Record on Inflammatory Short Report (Bloomberg)
05:28PM	S&P 500 Gains and Losses Today: Apple Jumps on Report of Plans for AI-Powered Macs (Investopedia)
05:02PM	Globe Life Inc. Issues Statement Refuting Short Seller Allegations (PR Newswire)
04:35PM	Globe Life Stock Plunges 53% After Short Seller Alleges Fraud (Investopedia)
04:00PM	US STOCKS-S&P 500, Nasdaq end sharply higher on soft inflation data, eyes on earnings (Reuters)
03:26PM	Insurer Globe Life Stock Slammed After Short-Seller Alleges Widespread Fraud (The Wall Street Journal)
03:19PM	Lowey Dannenberg, P.C. is Investigating Global Life Inc. ( Global Life ) (NYSE: GL) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm (GlobeNewswire)
11:58AM	Top Stock Movers Now: Nike, Constellation Brands, Fastenal, and More (Investopedia)
11:27AM	Fuzzy Panda Slams Globe Life (GL) Stock in New Short Report (InvestorPlace)
09:13AM	UPDATE 1-Fuzzy Panda Research discloses short position in Globe Life (Reuters)
09:06AM	Fuzzy Panda Research discloses short position in Globe Life (Reuters)
Apr-10-24 09:17AM	Here's Why You Should Add Globe Life (GL) to Your Portfolio (Zacks)
Apr-09-24 11:14AM	Warren Buffett's Portfolio: 15 Longest Held Stocks (Insider Monkey)
09:55AM	Here's Why Globe Life (GL) Looks Ripe for Bottom Fishing (Zacks)
Apr-04-24 07:26AM	Globe Life defends business model after short-seller criticism (Reuters)
Apr-03-24 11:45AM	Short-seller Koppikar sees insurer Globe Life as 'attractive' target (Reuters)
09:40AM	Is Globe Life (GL) Stock Undervalued Right Now? (Zacks)
Mar-18-24 04:10PM	GLOBE LIFE INC. DECLARES DIVIDEND (PR Newswire)
Mar-15-24 05:06AM	Here Are All 7 Stocks Warren Buffett Is Selling (Motley Fool)
Mar-08-24 11:30AM	Globe Life (GL) Up 1.8% Since Last Earnings Report: Can It Continue? (Zacks)
08:15AM	Here's Why You Should Buy Globe Life (GL) Stock Right Now (Zacks)
Feb-29-24 12:04AM	Decoding Globe Life Inc (GL): A Strategic SWOT Insight (GuruFocus.com)
Feb-13-24 09:15AM	Globe Life Inc. (GL) Hit a 52 Week High, Can the Run Continue? (Zacks)
Feb-09-24 12:00PM	Globe Life (GL) Moves to Buy: Rationale Behind the Upgrade (Zacks)
02:30AM	Q4 2023 Globe Life Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-08-24 08:42AM	Globe Life (GL) Q4 Earnings Beat on Solid Investment Income (Zacks)
Feb-07-24 06:00PM	Globe Life (GL) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:54PM	Globe Life profit rises on stronger underwriting, investment returns (Reuters)
05:25PM	Globe Life (GL) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
04:53PM	Globe Life Inc (GL) Reports Solid Growth in Q4 2023 Earnings (GuruFocus.com)
04:34PM	Globe Life: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	GLOBE LIFE INC. REPORTS FOURTH QUARTER 2023 RESULTS (PR Newswire)
Feb-06-24 12:10PM	Will Globe Life (GL) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Feb-05-24 09:16AM	What Analyst Projections for Key Metrics Reveal About Globe Life (GL) Q4 Earnings (Zacks)
07:00AM	GLOBE LIFE INC. ANNOUNCES FOURTH QUARTER 2023 EARNINGS RELEASE AND CONFERENCE CALL (PR Newswire)
Jan-31-24 10:00AM	Globe Life (GL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jan-25-24 06:21PM	GLOBE LIFE INC. ANNOUNCES FOURTH QUARTER 2023 EARNINGS RELEASE AND CONFERENCE CALL (PR Newswire)

Globe Life, Inc. is a holding company, which engages in the provision of individual life and supplemental health insurance products and services. It operates through the following segments: Life Insurance, Supplemental Health Insurance, Annuities, and Investments. The Life Insurance segment includes traditional and interest-sensitive whole life insurance as well as term life insurances. The Supplement Health Insurance segment provides generally guaranteed-renewable and include Medicare, critical illness, accident, and limited-benefit supplement hospital, and surgical coverage. The Annuities segment refers to fixed-benefit contracts. The Investments segment covers the investment portfolio. The company was founded on November 19, 1979, and is headquartered in McKinney, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BLINN MARK A	Director	Apr 25 '24	Buy	76.77	2,000	153,540	6,518	Apr 26 02:56 PM
Zorn Rebecca E	EVP & Chief Talent Officer	Apr 25 '24	Sale	77.30	2,320	179,336	10,220	Apr 26 12:45 PM
BRANNEN JAMES	Director	Apr 24 '24	Buy	78.47	2,000	156,940	7,030	Apr 26 12:14 PM
Rodriguez David A	Director	Apr 24 '24	Buy	79.72	1,500	119,585	4,192	Apr 26 12:33 PM
Johnson Steven Paul	Director	Apr 24 '24	Buy	76.42	1,319	100,800	14,766	Apr 26 12:29 PM
Haworth Jennifer Allison	EVP & Chief Marketing Officer	Dec 29 '23	Option Exercise	50.69	4,500	228,120	11,130	Dec 29 03:51 PM
Haworth Jennifer Allison	EVP & Chief Marketing Officer	Dec 29 '23	Sale	121.37	2,524	306,348	8,606	Dec 29 03:51 PM
BUCHAN JANE	Director	Dec 12 '23	Sale	124.50	1,000	124,500	80,285	Dec 13 04:47 PM
Skarjune Dolores L	EVP and Chief Admin. Officer	Dec 11 '23	Option Exercise	95.05	23,775	2,259,780	25,435	Dec 12 12:56 PM
Skarjune Dolores L	EVP and Chief Admin. Officer	Dec 11 '23	Sale	123.28	20,479	2,524,565	4,956	Dec 12 12:56 PM
Zorn Rebecca E	EVP & Chief Talent Officer	Nov 30 '23	Option Exercise	82.70	18,500	1,529,880	22,442	Dec 01 04:16 PM
Zorn Rebecca E	EVP & Chief Talent Officer	Nov 30 '23	Sale	122.08	13,990	1,707,910	8,452	Dec 01 04:16 PM
MAJORS MICHAEL CLAY	EVP - Chief Strategy Officer	Nov 21 '23	Option Exercise	83.23	15,000	1,248,480	50,015	Nov 22 10:07 AM
MAJORS MICHAEL CLAY	EVP - Chief Strategy Officer	Nov 21 '23	Sale	119.36	15,000	1,790,424	35,015	Nov 22 10:07 AM
SVOBODA FRANK M	Co-Chairman & CEO	Nov 17 '23	Option Exercise	77.26	9,500	733,970	12,870	Nov 20 09:43 AM
SVOBODA FRANK M	Co-Chairman & CEO	Nov 17 '23	Sale	118.22	9,500	1,123,056	3,370	Nov 20 09:43 AM
HENRIE MICHAEL SHANE	SVP & Chief Accounting Officer	Nov 15 '23	Option Exercise	100.33	6,800	682,249	7,500	Nov 16 11:10 AM
HENRIE MICHAEL SHANE	SVP & Chief Accounting Officer	Nov 15 '23	Sale	117.57	6,800	799,488	700	Nov 16 11:10 AM
SVOBODA FRANK M	Co-Chairman & CEO	Nov 06 '23	Option Exercise	77.26	20,000	1,545,200	23,370	Nov 07 04:06 PM
SVOBODA FRANK M	Co-Chairman & CEO	Nov 06 '23	Sale	115.92	20,000	2,318,496	3,370	Nov 07 04:06 PM
Darden James Matthew	Co-Chairman & CEO	Nov 03 '23	Option Exercise	77.26	9,551	737,910	34,621	Nov 06 05:27 PM
Darden James Matthew	Co-Chairman & CEO	Nov 03 '23	Sale	116.98	8,551	1,000,289	26,070	Nov 06 05:27 PM
HENRIE MICHAEL SHANE	SVP & Chief Accounting Officer	Oct 27 '23	Option Exercise	98.32	2,500	245,800	3,200	Oct 31 11:22 AM
HENRIE MICHAEL SHANE	SVP & Chief Accounting Officer	Oct 27 '23	Sale	113.05	2,500	282,630	700	Oct 31 11:22 AM
HENRIE MICHAEL SHANE	SVP & Chief Accounting Officer	Sep 12 '23	Option Exercise	98.32	2,500	245,800	3,200	Sep 13 05:52 PM
HENRIE MICHAEL SHANE	SVP & Chief Accounting Officer	Sep 12 '23	Sale	110.37	2,500	275,926	700	Sep 13 05:52 PM
MITCHELL ROBERT BRIAN	EVP, General Counsel and CRO	Aug 30 '23	Sale	111.97	16,217	1,815,766	36,635	Aug 31 04:08 PM
HENRIE MICHAEL SHANE	SVP & Chief Accounting Officer	Aug 29 '23	Option Exercise	93.55	1,325	123,954	2,025	Aug 30 12:32 PM
HENRIE MICHAEL SHANE	SVP & Chief Accounting Officer	Aug 29 '23	Sale	111.20	1,325	147,335	700	Aug 30 12:32 PM
SVOBODA FRANK M	Co-Chairman & CEO	Aug 16 '23	Option Exercise	77.26	12,500	965,750	15,870	Aug 17 05:58 PM
SVOBODA FRANK M	Co-Chairman & CEO	Aug 16 '23	Sale	113.57	12,500	1,419,574	3,370	Aug 17 05:58 PM
HENRIE MICHAEL SHANE	SVP & Chief Accounting Officer	Jul 31 '23	Option Exercise	87.60	1,000	87,600	1,700	Aug 01 11:17 AM
HENRIE MICHAEL SHANE	SVP & Chief Accounting Officer	Jul 31 '23	Sale	112.06	1,000	112,060	700	Aug 01 11:17 AM
Alston Cheryl	Director	Jun 14 '23	Option Exercise	79.31	16,691	1,323,767	22,929	Jun 15 05:03 PM
Alston Cheryl	Director	Jun 14 '23	Sale	108.81	16,691	1,816,184	6,238	Jun 15 05:03 PM

Open in Screener

IMMX

Immix Biopharma Inc

May 15 • 03:03PM ET

2.40

Dollar change +0.20
Percentage change 9.09	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC DFUS DCOR

Index	-	P/E	-	EPS (ttm)	-0.95	Insider Own	47.54%	Shs Outstand	19.92M	Perf Week	7.14%
Market Cap	63.38M	Forward P/E	-	EPS next Y	-1.01	Insider Trans	0.52%	Shs Float	13.86M	Perf Month	-6.61%
Income	-18.21M	PEG	-	EPS next Q	-	Inst Own	12.45%	Short Float	2.80%	Perf Quarter	-13.36%
Sales	0.00M	P/S	-	EPS this Y	-24.00%	Inst Trans	19.80%	Short Ratio	2.14	Perf Half Y	-43.53%
Book/sh	1.06	P/B	2.27	EPS next Y	-8.60%	ROA	-76.56%	Short Interest	0.39M	Perf Year	16.50%
Cash/sh	1.11	P/C	2.16	EPS next 5Y	-	ROE	-91.75%	52W Range	1.40 - 7.75	Perf YTD	-65.32%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-63.30%	ROI	-62.83%	52W High	-69.03%	Beta	0.22
Dividend TTM	-	Quick Ratio	5.82	Sales past 5Y	0.00%	Gross Margin	-	52W Low	71.43%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	5.82	EPS Y/Y TTM	-37.71%	Oper. Margin	0.00%	RSI (14)	50.83	Volatility	9.13% 11.86%
Employees	17	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	14.00
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	-25.78%	Payout	-	Rel Volume	0.56	Prev Close	2.20
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	180.96K	Price	2.40
SMA20	8.33%	SMA50	-9.92%	SMA200	-31.90%	Trades		Volume	86,747	Change	9.09%

May-13-24 09:53AM	IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024 (InvestorPlace)
May-10-24 09:35AM	Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation (GlobeNewswire)
Apr-29-24 02:50PM	Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment (MT Newswires)
09:39AM	Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma (GlobeNewswire)
Apr-18-24 09:37AM	Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States (GlobeNewswire) -11.60%
09:32AM	Loading…
09:32AM	Immix Biopharma on Track to Dose NXC-201 Patients in United States (GlobeNewswire)
Apr-15-24 09:36AM	Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire)
Apr-02-24 07:53AM	IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023 (InvestorPlace)
Mar-20-24 09:46AM	Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial (GlobeNewswire)
Mar-05-24 09:35AM	Immix Biopharma Announces Be Proactive in AL AL Amyloidosis Awareness Initiative (GlobeNewswire) -8.06%
Feb-21-24 09:31AM	Immix Biopharma 12 Month Review Progress Update (GlobeNewswire)
Feb-08-24 04:45PM	Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock (GlobeNewswire) +6.60%
Feb-07-24 09:37AM	Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis (GlobeNewswire) +7.07%
Feb-05-24 10:30PM	Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock (GlobeNewswire) -19.89%
03:20PM	Immix Biopharma Announces Proposed Public Offering of Common Stock (GlobeNewswire)
08:35AM	Loading…
Jan-24-24 08:35AM	Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products (GlobeNewswire)
Jan-04-24 09:34AM	Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board (GlobeNewswire)
Dec-18-23 09:39AM	Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board (GlobeNewswire) -8.94%
Dec-11-23 09:36AM	Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023 (GlobeNewswire)
Nov-30-23 09:46AM	Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-28-23 08:50AM	What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing' (Zacks) +5.39%
Nov-22-23 11:10AM	Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down (Zacks) +5.01%
09:19AM	Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis (GlobeNewswire)
Nov-21-23 09:46AM	Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing (GlobeNewswire)
Nov-06-23 09:18AM	Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients (GlobeNewswire) +20.73%
09:12AM	Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients (GlobeNewswire)
08:40AM	Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients (GlobeNewswire)
Oct-31-23 09:55AM	Here's Why Immix Biopharma, Inc. (IMMX) Is a Great 'Buy the Bottom' Stock Now (Zacks) +9.37%
Oct-26-23 08:58AM	Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board (GlobeNewswire)
Oct-16-23 09:05AM	Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site (GlobeNewswire)
09:14AM	Loading…
Oct-03-23 09:14AM	Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting (GlobeNewswire) +5.31%
Oct-02-23 08:06AM	Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma (GlobeNewswire) +26.61%
Sep-22-23 12:04PM	Immix (IMMX) Up on Orphan Drug Tag for AL Amyloidosis Therapy (Zacks)
Sep-21-23 08:55AM	U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis (GlobeNewswire) +15.38%
Sep-19-23 09:10AM	Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site (GlobeNewswire) +24.15%
Sep-15-23 01:18PM	Director Helen Adams Buys 13,000 Shares of Immix Biopharma Inc (IMMX) (GuruFocus.com) +5.12%
Sep-07-23 10:38AM	The 3 Best Speculative Stocks to Buy Now: September 2023 (InvestorPlace)
08:41AM	Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference (GlobeNewswire)
Sep-01-23 08:39AM	Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board (GlobeNewswire) +12.81%
Aug-23-23 08:37AM	U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma (GlobeNewswire) +11.11%
Aug-18-23 09:20AM	Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board (GlobeNewswire) +6.13%
Aug-16-23 09:05AM	Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece) (GlobeNewswire)
Jul-25-23 08:42AM	Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting (GlobeNewswire)
Jul-17-23 09:37AM	Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial (GlobeNewswire) -6.11%
Jul-10-23 09:47AM	Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site (GlobeNewswire)
Jun-26-23 09:49AM	Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial (GlobeNewswire) -6.90%
Jun-22-23 09:53AM	Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors (GlobeNewswire)
Jun-20-23 09:45AM	Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors (GlobeNewswire) +8.11%
Jun-16-23 09:43AM	Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors (GlobeNewswire) -5.93%
Jun-14-23 07:30AM	Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program (GlobeNewswire)
Jun-12-23 09:49AM	Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors (GlobeNewswire)
May-26-23 09:53AM	Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site (GlobeNewswire) +9.38%
May-22-23 01:48PM	Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis (Benzinga) +6.71%
08:31AM	We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-21-23 04:05PM	Nexcella Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial (GlobeNewswire)
04:00PM	Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial (GlobeNewswire)
May-04-23 12:30PM	Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire)
May-03-23 04:42PM	What's Going On With Immix Biopharma Stock Today (Benzinga)
08:00AM	Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab (GlobeNewswire)
Apr-26-23 05:30PM	Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris (GlobeNewswire)
Apr-04-23 08:00AM	Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting (GlobeNewswire) -7.45%
Mar-31-23 08:00AM	Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells (GlobeNewswire) +5.81%
Mar-23-23 08:00AM	Nexcella, an Immix Biopharma Subsidiary, Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential (GlobeNewswire) -7.94%
Mar-10-23 07:45PM	Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank (GlobeNewswire) -7.69%
Mar-06-23 08:00AM	ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14 (GlobeNewswire)
Feb-27-23 08:45AM	Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission (GlobeNewswire)
Feb-15-23 08:30AM	Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S. (GlobeNewswire)
Feb-09-23 08:00AM	Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting (GlobeNewswire) -16.59%
Feb-07-23 08:00AM	Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer (GlobeNewswire) -8.01%
Jan-13-23 08:00AM	Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial (GlobeNewswire)
Jan-06-23 08:00AM	Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached (GlobeNewswire) -8.24%
Dec-28-22 08:00AM	Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting (GlobeNewswire) +8.50%
Dec-20-22 08:00AM	Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial (GlobeNewswire) -5.08%
Dec-19-22 08:00AM	ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors (GlobeNewswire)
Dec-14-22 12:43PM	Why Immix Biopharma Shares Are Surging Today? (Benzinga) +23.29%
08:00AM	Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses) (GlobeNewswire)
Dec-13-22 08:00AM	Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial (GlobeNewswire)
05:06AM	We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely (Simply Wall St.)
Dec-12-22 08:00AM	ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing (GlobeNewswire) +7.91%
Nov-11-22 08:00AM	Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher (GlobeNewswire) +16.67%
Oct-25-22 08:00AM	Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26 (GlobeNewswire)
Oct-18-22 08:00AM	ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site (GlobeNewswire)
Sep-07-22 12:05PM	ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials (GlobeNewswire)
Aug-23-22 06:36AM	Insiders who bought in the last 12 months lose an additional US$175k as Immix Biopharma, Inc. (NASDAQ:IMMX) drops to US$28m (Simply Wall St.)
Aug-01-22 10:10AM	10 Best Penny Stocks to Buy and Hold According to Reddit (Insider Monkey)
May-21-22 08:26AM	We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth (Simply Wall St.)
May-20-22 10:19AM	ImmixBio's Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug (Benzinga) +30.06%
08:47AM	ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study (GlobeNewswire)
May-09-22 08:00AM	Immix Biopharma Announces Share Repurchase Program (GlobeNewswire)
Apr-05-22 09:30AM	ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022 (GlobeNewswire) -22.01%
Mar-16-22 10:13AM	Multiple insiders bought Immix Biopharma, Inc. (NASDAQ:IMMX) stock earlier this year, a positive sign for shareholders (Simply Wall St.) +19.12%
Mar-07-22 08:00AM	Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022 (GlobeNewswire) -10.90%
Feb-22-22 08:00AM	ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease (GlobeNewswire) -9.50%
Feb-01-22 11:36AM	5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI (InvestorPlace) +13.55%
09:30AM	ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022 (GlobeNewswire)
Jan-31-22 08:00AM	ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data (GlobeNewswire)
Jan-25-22 12:17PM	Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies (Benzinga)
10:15AM	IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale (GlobeNewswire)
Jan-19-22 08:00AM	ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles (GlobeNewswire)
Jan-12-22 08:43AM	Immix's Lead Program Shows 50% Response Rate In Resistant Cancer In Animal Study (Benzinga) +18.42%

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Morris Gabriel S	CFO	May 14 '24	Buy	2.23	4,500	10,042	85,816	May 14 09:29 PM
Rachman Ilya M	CEO and Chairman	May 14 '24	Buy	2.25	4,300	9,660	912,000	May 14 09:28 PM
Hsu Jason	Director	Dec 11 '23	Buy	4.67	31,000	144,894	813,000	Dec 12 06:25 PM
Hsu Jason	Director	Dec 08 '23	Buy	4.88	25,000	122,025	782,000	Dec 12 06:25 PM
Hsu Jason	Director	Sep 15 '23	Buy	2.49	7,000	17,396	757,000	Sep 18 07:03 PM
Hsu Jason	Director	Sep 14 '23	Buy	2.58	10,000	25,772	750,000	Sep 18 07:03 PM
Ng Carey	Director	Sep 14 '23	Buy	2.58	10,000	25,760	10,000	Sep 15 06:27 PM
Hsu Jason	Director	Sep 12 '23	Buy	2.83	30,000	84,864	740,000	Sep 18 07:03 PM
Adams Helen C.	Director	Sep 12 '23	Buy	2.96	13,000	38,492	13,000	Sep 14 05:20 PM
Hsu Jason	Director	Sep 11 '23	Buy	2.89	25,000	72,280	710,000	Sep 18 07:03 PM
Hsu Jason	Director	Sep 08 '23	Buy	2.53	10,000	25,317	685,000	Sep 12 04:58 PM
BUCHAN MELISSA JANE	Director	Sep 07 '23	Buy	2.46	20,000	49,226	20,000	Sep 11 05:18 PM
Marquet Magda	Director	Sep 06 '23	Buy	2.47	9,000	22,213	20,000	Sep 08 05:46 PM
Marquet Magda	Director	Sep 05 '23	Buy	2.47	10,000	24,722	11,000	Sep 06 04:33 PM
Marquet Magda	Director	Aug 31 '23	Buy	2.01	1,000	2,010	1,000	Sep 05 06:43 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

GL

Globe Life Inc

IMMX

Immix Biopharma Inc

Upgrade your FINVIZ experience